Vera Therapeutics, Inc. $VERA Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC reduced its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 52.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,651 shares of the company’s stock after selling 13,743 shares during the quarter. SG Americas Securities LLC’s holdings in Vera Therapeutics were worth $509,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. UBS Group AG lifted its position in shares of Vera Therapeutics by 27.9% during the fourth quarter. UBS Group AG now owns 207,289 shares of the company’s stock worth $10,497,000 after purchasing an additional 45,214 shares in the last quarter. Hudson Bay Capital Management LP increased its stake in Vera Therapeutics by 47.4% during the 3rd quarter. Hudson Bay Capital Management LP now owns 440,591 shares of the company’s stock worth $12,804,000 after buying an additional 141,615 shares during the period. Schroder Investment Management Group increased its stake in Vera Therapeutics by 82.4% during the 3rd quarter. Schroder Investment Management Group now owns 679,992 shares of the company’s stock worth $19,652,000 after buying an additional 307,243 shares during the period. Vanguard Group Inc. lifted its holdings in Vera Therapeutics by 11.9% in the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after buying an additional 379,748 shares in the last quarter. Finally, Braidwell LP acquired a new position in Vera Therapeutics in the 3rd quarter worth $13,738,000. 99.21% of the stock is owned by institutional investors and hedge funds.

Key Vera Therapeutics News

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: The FDA approved TRUTAKNA for primary IgA nephropathy, making it the first and only available therapy targeting both BAFF and APRIL for this kidney disease. Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA for Adult Patients with Primary IgA Nephropathy
• Positive Sentiment: Multiple reports said the approval triggered a sharp move in the stock, with investors viewing the drug approval as a key commercial catalyst for Vera Therapeutics. US FDA approves Vera’s kidney disease drug
• Positive Sentiment: Analysts responded favorably after the approval, including HC Wainwright raising its price target to $125 and Bank of America lifting its target to $70, reinforcing expectations for meaningful upside if TRUTAKNA gains traction.
• Neutral Sentiment: Wedbush also increased its price target to $43 and kept a neutral rating, suggesting the approval improved sentiment but left some analysts more cautious on valuation.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 22,951 shares of the stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55. Following the transaction, the chief executive officer owned 235,244 shares of the company’s stock, valued at $10,362,498.20. This trade represents a 8.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 59,951 shares of company stock worth $2,392,387. Company insiders own 15.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Evercore set a $91.00 target price on Vera Therapeutics in a research note on Friday, May 15th. TD Cowen boosted their price target on Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. The Goldman Sachs Group reissued a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Finally, William Blair restated an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $84.58.

Vera Therapeutics Trading Down 1.2%

VERA opened at $42.43 on Thursday. The stock has a market capitalization of $3.05 billion, a PE ratio of -7.66 and a beta of 0.92. The firm’s fifty day moving average price is $36.40 and its 200 day moving average price is $41.16. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. Vera Therapeutics, Inc. has a 12-month low of $19.07 and a 12-month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the business earned ($0.81) EPS. As a group, research analysts expect that Vera Therapeutics, Inc. will post -6.23 EPS for the current fiscal year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.